Kimberly-Clark
KMB
$107.94
-1.89%
Kimberly-Clark is a global consumer staples manufacturer whose portfolio spans personal care (Huggies, Pull-Ups, Kotex, Depend), consumer tissue (Kleenex, Cottonelle, Scott) and a professional away-from-home business supplying workplace hygiene and safety solutions, with roughly half of sales generated in North America and the balance spread across Europe, Asia and Latin America. The company is a mature, brand-moat-driven category leader in tissue and hygiene rather than a growth disruptor, competing on shelf space, brand trust and scale-driven cost advantages against Procter & Gamble, Essity and private-label challengers. The dominant investor narrative today is the pending absorption of Kenvue's consumer health portfolio, slated to close in the second half of calendar 2026, which would transform Kimberly-Clark from a slow-growth staples operator into a larger health-and-hygiene platform and is the central debate around integration risk, leverage and dilution. That strategic pivot is layered atop a stock that has lagged the market badly over the past year while offering an unusually high dividend yield, creating a split narrative between income/value buyers and investors worried about margin pressure and deal execution.…
KMB
Kimberly-Clark
$107.94
Related headlines
Investment Opinion: Should I buy KMB Today?
Rating: Hold. Kimberly-Clark is a high-yield defensive staple with a 4.94% dividend and a discounted 14.9x forward P/E, but flat revenue growth and margin compression offset the income appeal. The analyst consensus is 'buy' with an average target of $114.80, implying only 4.2% upside, suggesting the stock is fairly valued near current levels. The primary support for the rating is the dividend yield, which is nearly 5% and backed by $2.56B in trailing free cash flow, though the 82% payout ratio limits flexibility. Valuation is reasonable at 16.6x trailing earnings and 1.95x sales, below the market multiple, but not deep enough to compensate for the lack of growth. Revenue growth of 0.62% year-over-year and operating margin contraction from 14.2% to 10.7% are red flags that prevent a more positive stance. The biggest risks are integration and dilution from the Kenvue acquisition, a potential dividend cut if cash flow weakens, and continued market share loss to private label. The rating would upgrade to Buy if the Kenvue deal closes smoothly, debt is managed below 4x EBITDA, and revenue growth accelerates above 2%. It would downgrade to Sell if the dividend is cut or if operating margins fall below 10%. Relative to its own history and peers, KMB appears fairly valued to slightly undervalued on earnings, but the lack of growth justifies a hold.
Sign up to view all
KMB 12-Month Price Forecast
KMB presents a balanced risk/reward: the 4.94% dividend yield and discounted 14.9x forward P/E provide a margin of safety, but flat revenue growth and margin compression limit upside. The analyst consensus target of $114.80 implies only 4.2% upside, and the stock has already rebounded 12.7% in the past month, reducing the near-term cushion. The Kenvue deal is the wild card—successful integration could re-rate the stock toward $123-$162, while missteps could push it back to $90-$100. I would upgrade to bullish if operating margins stabilize above 12% and revenue growth accelerates above 2%, or if the Kenvue deal closes with less dilution than feared. I would downgrade to bearish if the dividend is cut or if debt-to-equity rises above 5.5x.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kimberly-Clark's 12-month outlook, with a consensus price target around $114.63 and implied upside of +6.2% versus the current price.
Average Target
$114.63
0 analysts
Implied Upside
+6.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $162
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: KMB Investment Factors
The bear case currently has stronger near-term evidence: revenue growth is flat at 0.6%, operating margins have compressed from 14.2% to 10.7% year-over-year, and the stock has lagged the S&P 500 by over 20 percentage points in the past year. However, the bull case rests on a 4.94% dividend yield, a discounted 14.9x forward P/E, and the transformative Kenvue acquisition that could re-rate the business. The single most important tension is whether the Kenvue integration can be executed without damaging the balance sheet (already 4.86x debt-to-equity) or the dividend, versus the risk that KMB remains a low-growth staples operator with stagnant volumes. Resolution of this debate will determine whether the stock re-rates toward the $162 high target or drifts back toward the $92 low.
Bullish
- Dividend yield near 5%: KMB offers a 4.94% dividend yield, roughly 4x the S&P 500's yield, backed by $2.56B in trailing free cash flow. The payout ratio of 82% is elevated but supported by stable staples cash generation, making the stock a compelling income vehicle.
- Analyst consensus buy with upside: 15 analysts rate KMB a 'buy' (mean 2.44) with an average target of $114.80, implying 4.2% upside from $110.15 and a high target of $162 (+47%). The consensus EPS estimate of $8.79 suggests confidence in earnings resilience despite deal-related noise.
- Valuation below market multiples: KMB trades at 16.6x trailing and 14.9x forward earnings, a discount to the broader market and well below its own historical premium as a staples leader. EV/EBITDA of 12.2x and P/S of 1.95x are reasonable for a business with 11.7% net margins and brand moats.
- Kenvue deal transforms growth profile: The pending acquisition of Kenvue's consumer health portfolio, expected to close in H2 2026, would add high-margin health brands and diversify KMB beyond slow-growth tissue and personal care. This is a potential re-rating catalyst if integration is executed well.
Bearish
- Revenue growth is essentially flat: Q2 2026 revenue grew just 0.62% year-over-year to $4.19B, and Q1 2026 revenue of $4.16B was down sharply from $4.84B in Q1 2025. Organic growth is anemic, and the company relies on pricing rather than volume, which limits operating leverage.
- Margins are compressing: Q2 2026 gross margin of 38.3% improved sequentially but operating margin fell to 10.7% from 14.2% a year ago, and net margin dropped to 8.2% from 12.2%. Rising SG&A and deal-related costs are eroding profitability despite modest sales gains.
- Balance sheet leverage is extreme: Debt-to-equity stands at 4.86x and the current ratio is only 0.75, indicating thin liquidity. The Kenvue acquisition will likely add significant debt, increasing financial risk and potentially pressuring the dividend if cash flow disappoints.
- Stock has badly lagged the market: KMB is down 7.25% over the past year while the S&P 500 gained 13.13%, a relative underperformance of 20.4 percentage points. The 52-week range of $92.42-$123.09 shows the stock is still 10.5% below its high despite a recent rebound.
KMB Technical Analysis
Beta
0.28
0.28x market volatility
Max Drawdown
-25.2%
Largest decline past year
52-Week Range
$92-$120
Price range past year
Annual Return
-10.2%
Cumulative gain past year
| Period | KMB Return | S&P 500 |
|---|---|---|
| 1m | +10.8% | -0.9% |
| 3m | -1.3% | +1.2% |
| 6m | +10.5% | +4.9% |
| 1y | -10.2% | +11.2% |
| ytd | +6.4% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KMB Fundamental Analysis
Quarterly Revenue
$4.2B
2026-06
Revenue YoY Growth
+0.6%
YoY Comparison
Gross Margin
38.3%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KMB Overvalued?
PE
16.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. Debt-to-equity of 4.86x is among the highest in consumer staples, and the current ratio of 0.75 signals limited short-term liquidity. The pending Kenvue acquisition will likely require additional debt or equity issuance, further straining the balance sheet. Meanwhile, operating margin has fallen from 14.2% in Q2 2025 to 10.7% in Q2 2026, and net margin dropped from 12.2% to 8.2%, showing that cost pressures and deal-related expenses are already biting. Revenue growth of just 0.62% year-over-year provides little cushion to absorb these costs, and the 82% payout ratio leaves limited room for error on the dividend. Market and competitive risks include valuation compression if the stock's premium to peers erodes, though at 14.9x forward earnings KMB is not expensive relative to history. However, private-label competition in tissue and personal care, particularly from retailers expanding own brands, threatens pricing power. The low beta of 0.275 means the stock is less sensitive to market swings, but it also limits upside in strong rallies; indeed, KMB underperformed the S&P 500 by 20.4 percentage points over the past year. Regulatory scrutiny of the Kenvue deal and potential antitrust conditions could delay or alter the transaction, adding uncertainty. The worst-case scenario involves a combination of Kenvue integration missteps, a dividend cut to preserve cash, and a return to revenue declines. In that scenario, the stock could retest its 52-week low of $92.42, representing a 16.1% decline from the current $110.15. If the deal triggers significant dilution and margins continue to compress, the analyst low target of $90 would imply an 18.3% downside. Given the max drawdown of 25.86% over the past year, a similar drawdown from current levels would take the stock to roughly $81.70, though that is more extreme than the base case.
FAQ
The most severe risk is financial: debt-to-equity of 4.86x and a current ratio of 0.75 leave little flexibility, and the Kenvue acquisition could worsen leverage. Second, margin compression is a threat, with operating margin falling from 14.2% to 10.7% year-over-year. Third, competitive pressure from private-label brands could erode market share in tissue and personal care, limiting pricing power. Fourth, integration risk from Kenvue could lead to earnings misses or dilution. Finally, the 82% payout ratio means a dividend cut is possible if cash flow weakens, which would likely trigger a sharp selloff.
Our 12-month forecast has three scenarios: bull case (25% probability) targeting $123-$162 if Kenvue integration succeeds and margins expand; base case (50% probability) targeting $105-$120 with modest growth and stable margins; and bear case (25% probability) targeting $90-$100 if integration falters or a dividend cut occurs. The base case is most likely, assuming the Kenvue deal closes with manageable dilution and organic growth remains around 1-2%. The key assumption is that operating margins stabilize near 11-12% and the dividend is maintained.
KMB appears fairly valued to slightly undervalued. The trailing P/E of 16.6x and forward P/E of 14.9x are below the broader market's multiple, and the P/S of 1.95x is modest for a staples company with 11.7% net margins. However, the stock is not cheap on an absolute basis given its flat revenue growth; the PEG ratio is negative due to minimal earnings growth. Compared to its own history, KMB typically traded at a premium to the market, so the current discount reflects growth concerns. The market is pricing in modest expectations, with upside if the Kenvue deal unlocks growth.
KMB is a reasonable buy for income-focused investors, but not a compelling growth opportunity. The stock offers a 4.94% dividend yield, nearly 5x the S&P 500's yield, and trades at 14.9x forward earnings, below the market multiple. Analyst consensus is 'buy' with an average target of $114.80, implying 4.2% upside, though the high target of $162 suggests more potential if the Kenvue deal succeeds. The biggest downside risk is a dividend cut or integration missteps that could push the stock toward $90, an 18% decline. Therefore, KMB is a good buy for patient investors seeking defensive income, but those seeking capital appreciation should look elsewhere.
KMB is best suited for long-term, income-oriented investors. Its low beta of 0.275 and stable staples business provide downside protection, but the flat revenue growth and margin pressure limit short-term trading upside. The 4.94% dividend yield rewards patience, and the Kenvue acquisition could create value over a multi-year horizon if integration succeeds. Short-term traders may find opportunities around the deal closing or earnings, but the stock's low volatility makes it less ideal for momentum strategies. A minimum holding period of 2-3 years is recommended to capture the dividend and potential re-rating.